Clinical Trials · NCT01657162

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Name: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Abaloparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Radius Health, Inc.
Enrollment: 1,139
Start date: Nov 2012
Locations: 25 sites, 10 countries
Primary endpoint: Number of Participants With ≥1 New Vertebral Fracture Since Study BA058-05-003 Baseline

View Abaloparatide compound reference